NNVC - NanoViricides Inc Stock Price, Fair Value and News
2.09USD-0.14 (-6.28%)Delayed
Market Summary
USD2.09-0.14
Delayed-6.28%
NNVC Stock Price
View Fullscreen
NNVC RSI Chart
NNVC Valuation
NNVC Price/Sales (Trailing)
NNVC Profitability
NNVC Fundamentals
NNVC Earnings
Breaking Down NNVC Revenue
Last 7 days
10.6%
Last 30 days
80.2%
Last 90 days
69.9%
Trailing 12 Months
86.8%
How does NNVC drawdown profile look like?
NNVC Financial Health
NNVC Investor Care
Tracking the Latest Insider Buys and Sells of NanoViricides Inc
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Aug 08, 2022 | diwan anil | gifted | - | - | -94,471 | president |
Which funds bought or sold NNVC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| May 15, 2024 | STATE STREET CORP | unchanged | - | 5,867 | 48,611 | -% |
| May 15, 2024 | CITADEL ADVISORS LLC | added | 27.75 | 7,770 | 24,927 | -% |
| May 15, 2024 | Royal Bank of Canada | unchanged | - | 4,000 | 35,000 | -% |
| May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 8,265 | 68,485 | -% |
| May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 704 | 704 | -% |
| May 15, 2024 | Main Street Group, LTD | unchanged | - | 56.00 | 260 | -% |
| May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 488 | 488 | -% |
| May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -12.28 | - | 116 | -% |
| May 15, 2024 | MORGAN STANLEY | unchanged | - | 33.00 | 275 | -% |
| May 14, 2024 | Clearstead Advisors, LLC | unchanged | - | 235 | 534 | -% |
Are Funds Buying or Selling NNVC?
Calls
Puts
Net Call Options
No. of Funds
Unveiling NanoViricides Inc's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 16, 2021 | cvi investments, inc. | - | 0 | SC 13G/A | |
| Feb 12, 2021 | altium capital management lp | 0% | 0 | SC 13G/A | |
| Jan 26, 2021 | empery asset management, lp | 0.00% | 0 | SC 13G/A | |
| Jan 04, 2021 | sabby management, llc | 12.% | 0 | SC 13G/A | |
| Jul 20, 2020 | altium capital management lp | 7.2% | 750,000 | SC 13G | |
| May 29, 2020 | cvi investments, inc. | 5.1% | 466,667 | SC 13G | |
| Jan 27, 2020 | empery asset management, lp | 5.67% | 381,728 | SC 13G | |
| Jan 24, 2020 | sabby management, llc | 9.51% | 640,000 | SC 13G/A |
Recent SEC filings of NanoViricides Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 15, 2024 | 10-Q | Quarterly Report | |
| Apr 05, 2024 | 8-K | Current Report | |
| Apr 05, 2024 | 424B5 | Prospectus Filed | |
| Feb 16, 2024 | 8-K | Current Report | |
| Feb 14, 2024 | 10-Q | Quarterly Report |
Peers (Alternatives to NanoViricides Inc)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | 28.49% | 6.05% | -8.53 | 7.44 | -64.45% | -224.75% |
HILS | 22.5B | 216.3K | -0.77% | 465779.94% | -2.5K | 104.0K | - | -8.13% |
ALNY | 18.9B | 2.0B | 2.79% | -21.33% | -56.9 | 9.43 | 75.20% | 68.82% |
BMRN | 14.7B | 2.5B | -14.30% | -15.94% | 71.65 | 5.96 | 13.74% | 186.89% |
INCY | 12.8B | 3.8B | 8.33% | -10.25% | 17.2 | 3.4 | 8.58% | 129.81% |
| MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | 20.58% | 115.45% | -10.31 | 48.09 | 54.84% | -28.31% |
APLS | 5.0B | 524.1M | -13.99% | -52.79% | -12.02 | 9.57 | 394.93% | 39.61% |
AXSM | 3.6B | 251.0M | 9.96% | -0.29% | -12.28 | 14.5 | 73.58% | -86.73% |
ARWR | 3.1B | 240.7M | 9.94% | -31.73% | -6.53 | 12.77 | -1.03% | -213.43% |
ACAD | 2.4B | 813.8M | -14.08% | -36.34% | -1.4K | 3 | 56.43% | 98.83% |
| SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 3.06% | 35.16% | 29.91 | 4.73 | 60.38% | -34.49% |
NVAX | 1.8B | 996.6M | 233.93% | 75.07% | -4.58 | 1.83 | -26.66% | 65.49% |
CRBP | 480.9M | 881.7K | 21.10% | 351.81% | -14.25 | 481.06 | -77.61% | 33.36% |
INO | 310.9M | 4.9M | 8.40% | 53.85% | -2.49 | 63.89 | -54.97% | 48.23% |
IBIO | 17.1M | 2.1M | 4.76% | 108.64% | -0.74 | 7.61 | -13.45% | 69.54% |
NanoViricides Inc News
Latest updates
NanoViricides Inc Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Assets | -14.5% | 11.00 | 13.00 | 15.00 | 17.00 | 19.00 | 20.00 | 22.00 | 23.00 | 25.00 | 27.00 | 29.00 | 30.00 | 33.00 | 28.00 | 32.00 | 24.00 | 17.00 | 12.00 | 12.00 | 13.00 | 15.00 |
| Current Assets | -33.9% | 4.00 | 5.00 | 7.00 | 8.00 | 10.00 | 12.00 | 13.00 | 14.00 | 16.00 | 18.00 | 20.00 | 21.00 | 23.00 | 18.00 | 22.00 | 14.00 | 6.00 | 1.00 | 1.00 | 3.00 | 5.00 |
| Cash Equivalents | -37.4% | 3.00 | 5.00 | 7.00 | 8.00 | 10.00 | 11.00 | 13.00 | 14.00 | 16.00 | 17.00 | 20.00 | 21.00 | 23.00 | 18.00 | 22.00 | 14.00 | 6.00 | 1.00 | 1.00 | 3.00 | 4.00 |
| Net PPE | -1.8% | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Liabilities | -14.5% | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 |
| Current Liabilities | -14.5% | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | 0.00 | 2.00 | 2.00 | 2.00 | 4.00 | 3.00 | 3.00 | 1.00 |
| Shareholder's Equity | -14.5% | 11.00 | 12.00 | 13.00 | 15.00 | 18.00 | 20.00 | 22.00 | 23.00 | 25.00 | 26.00 | 28.00 | 30.00 | 32.00 | 28.00 | 30.00 | 22.00 | 14.00 | 8.00 | 9.00 | 11.00 | 13.00 |
| Retained Earnings | -1.4% | -137 | -135 | -133 | -131 | -127 | -125 | -124 | -122 | -121 | -118 | -117 | -114 | -112 | -110 | -107 | -105 | -103 | -95.61 | -93.70 | -92.12 | -89.90 |
| Additional Paid-In Capital | 0.0% | 148 | 148 | 146 | 146 | 146 | 146 | 146 | 146 | 145 | 145 | 145 | 144 | 144 | 138 | 138 | 127 | 118 | 103 | 103 | 103 | 103 |
| Accumulated Depreciation | - | 7.00 | - | - | 7.00 | - | - | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | - | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Shares Outstanding | 0.3% | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 11.00 | - | - | - | - | - | - | - | - |
| Float | - | - | - | - | - | - | 12.00 | - | - | - | 41.00 | - | - | - | 30.00 | - | - | - | - | - | - | - |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Cashflow From Operations | -11.8% | -1,900 | -1,700 | -1,200 | -1,500 | -1,766 | -1,400 | -1,032 | -1,397 | -1,655 | -2,114 | -724 | -2,227 | -1,434 | -2,315 | -2,235 | -1,708 | -2,396 | -1,126 | -1,434 | -1,671 | -2,010 |
| Cashflow From Investing | - | - | - | - | -2.57 | - | - | - | -170 | - | - | - | - | -110 | - | - | - | - | - | - | - | - |
| Cashflow From Financing | - | - | - | - | - | - | -23.84 | -70.95 | -32.71 | -69.29 | -61.37 | -71.34 | -70.50 | 6,052 | -1,074 | 10,354 | 9,316 | 7,795 | 959 | -242 | - | 2,350 |
NNVC Income Statement
2024-03-31Condensed Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
| OPERATING EXPENSES | ||||
| Research and development | $ 1,214,661 | $ 1,196,094 | $ 4,255,205 | $ 3,479,463 |
| General and administrative | 693,742 | 614,647 | 1,869,545 | 1,787,632 |
| Total operating expenses | 1,908,403 | 1,810,741 | 6,124,750 | 5,267,095 |
| LOSS FROM OPERATIONS | (1,908,403) | (1,810,741) | (6,124,750) | (5,267,095) |
| OTHER INCOME (EXPENSE) | ||||
| Interest income | 53,927 | 107,937 | 236,399 | 249,453 |
| Interest expense | (49,808) | (938) | ||
| Other income (expense), net | 53,927 | 107,937 | 186,591 | 248,515 |
| NET LOSS | $ (1,854,476) | $ (1,702,804) | $ (5,938,159) | $ (5,018,580) |
| Net loss/Weighted average common shares | ||||
| Net loss per common share- basic | $ (0.16) | $ (0.15) | $ (0.51) | $ (0.43) |
| Net loss per common share- diluted | $ (0.16) | $ (0.15) | $ (0.51) | $ (0.43) |
| Weighted average common shares outstanding - basic | 11,779,579 | 11,636,041 | 11,747,978 | 11,612,735 |
| Weighted average common shares outstanding - diluted | 11,779,579 | 11,636,041 | 11,747,978 | 11,612,735 |
NNVC Balance Sheet
2024-03-31Condensed Balance Sheets - USD ($) | Mar. 31, 2024 | Jun. 30, 2023 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 3,257,240 | $ 8,149,808 |
| Prepaid expenses | 258,548 | 295,486 |
| Total current assets | 3,515,788 | 8,445,294 |
| Property and equipment, net | 7,602,835 | 8,106,647 |
| Intangible assets, net | 327,376 | 333,578 |
| OTHER ASSETS | ||
| Service agreements | 18,908 | 14,361 |
| Total assets | 11,464,907 | 16,899,880 |
| CURRENT LIABILITIES: | ||
| Accrued expenses | 258,795 | 143,760 |
| Total current liabilities | 813,337 | 534,250 |
| Other non-current liability - related party | 1,500,000 | |
| Total liabilities | 813,337 | 2,034,250 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS' EQUITY: | ||
| Common stock, $0.00001 par value; 150,000,000 shares authorized, 11,813,867 and 11,698,497 shares issued and outstanding, at March 31, 2024 and June 30, 2023, respectively | 118 | 116 |
| Additional paid-in capital | 147,670,351 | 145,946,258 |
| Accumulated deficit | (137,018,908) | (131,080,749) |
| Total stockholders' equity | 10,651,570 | 14,865,630 |
| Total liabilities and stockholders' equity | 11,464,907 | 16,899,880 |
| Nonrelated party | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 341,394 | 157,056 |
| Related party | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 213,148 | 233,434 |
| Series A convertible preferred stock | ||
| STOCKHOLDERS' EQUITY: | ||
| Series A convertible preferred stock, $0.00001 par value, 10,000,000 shares designated, 892,238 and 547,674 shares issued and outstanding, at March 31, 2024 and June 30, 2023, respectively | $ 9 | $ 5 |
| CEO | Dr. Anil R. Diwan Ph.D. |
|---|---|
| WEBSITE | nanoviricides.com |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 17 |